Global Blood Therapeutics (GB:0IVZ)
LSE:0IVZ
UK Market

Global Blood Therapeutics Stock Analysis & Ratings

GB:0IVZ Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $0.00
Previous Close$26.47
VolumeN/A
Average Volume (3M)216.00
Market Cap$1.72B
P/E RatioN/A
Beta31.79
Next EarningsAug 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score6
EPS (TTM)0.00


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

GB:0IVZ FAQ

What was Global Blood Therapeutics’s price range in the past 12 months?
Global Blood Therapeutics lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Global Blood Therapeutics’s market cap?
    Global Blood Therapeutics’s market cap is $1.72B.
      What is Global Blood Therapeutics’s price target?
      The average price target for Global Blood Therapeutics is $57.50. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $75.00 ,the lowest forecast is $31.00. The average price target represents 117.23% Increase from the current price of $26.47.
        What do analysts say about Global Blood Therapeutics?
        Global Blood Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
          When is Global Blood Therapeutics’s upcoming earnings report date?
          Global Blood Therapeutics’s upcoming earnings report date is Aug 10, 2022 which is in 75 days.
            How were Global Blood Therapeutics’s earnings last quarter?
            Global Blood Therapeutics released its earnings results on May 04, 2022. The company reported -$1.26 earnings per share for the quarter, beating the consensus estimate of -$1.309 by $0.049.
              Is Global Blood Therapeutics overvalued?
              According to Wall Street analysts Global Blood Therapeutics’s price is currently Undervalued.
                Does Global Blood Therapeutics pay dividends?
                Global Blood Therapeutics does not currently pay dividends.
                What is Global Blood Therapeutics’s EPS estimate?
                Global Blood Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Global Blood Therapeutics have?
                Global Blood Therapeutics has 65,100,000 shares outstanding.
                  What happened to Global Blood Therapeutics’s price movement after its last earnings report?
                  Global Blood Therapeutics reported an EPS of -$1.26 in its last earnings report, beating expectations of -$1.309. Following the earnings report the stock price went same 0%.
                    Which hedge fund is a major shareholder of Global Blood Therapeutics?
                    Among the largest hedge funds holding Global Blood Therapeutics’s share is Perceptive Advisors LLC. It holds Global Blood Therapeutics’s shares valued at 135M.

                      ---

                      Global Blood Therapeutics Stock Analysis

                      The Global Blood Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Global Blood Therapeutics

                      Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Bellicum Pharmaceuticals
                      Aravive
                      SAGE Therapeutics
                      Seres Therapeutics

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis